Belite Bio Management

Management criteria checks 2/4

Belite Bio's CEO is Tom Lin, appointed in Nov 2021, has a tenure of 4.08 years. directly owns 1% of the company’s shares, worth $57.89M. The average tenure of the management team and the board of directors is 4.1 years and 3.7 years respectively.

Key information

Tom Lin

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.1yrs
CEO ownership	1.0%
Management average tenure	4.1yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Jul 02

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

CEO

Tom Lin (47 yo)

4.1yrs

Tenure

Dr. Yu-Hsin Lin, also known as Tom, MBA MMed PhD (Med) is the founder and has served as Director of Belite Bio, Inc since March 2018 and its Chairman and served as the Chief Executive Officer since Novembe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	4.1yrs	no data	1.0% $ 57.9m
Hao-Yuan Chuang	CFO & Director	5.7yrs	no data	0.22% $ 12.8m
Nathan Mata	Chief Scientific Officer	4.1yrs	no data	no data
Hendrik Scholl	Chief Medical Officer	1.3yrs	no data	no data

4.1yrs

Average Tenure

51.5yo

Average Age

Experienced Management: BLTE's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yu-Hsin Lin	Chairman of the Board of Directors & CEO	7.8yrs	no data	1.0% $ 57.9m
Hao-Yuan Chuang	CFO & Director	4.1yrs	no data	0.22% $ 12.8m
Frank Holz	Member of Ophthalmology Clinical Advisory Board	no data	no data	no data
Yuan Lu	Independent Director	3.7yrs	no data	no data
Quan Dong Nguyen	Member of Ophthalmology Clinical Advisory Board	no data	no data	no data
Michel Michaelides	Member of Ophthalmology Clinical Advisory Board	no data	no data	no data
Wan-Shan Chen	Director	4.1yrs	no data	no data
John Longo	Independent Director	3.7yrs	no data	no data
Gary Biddle	Independent Director	3.7yrs	no data	no data
Xiao-Hui Chen	Director	less than a year	no data	no data
Robyn Guymer	Member of Ophthalmology Clinical Advisory Board	no data	no data	no data

3.7yrs

Average Tenure

47yo

Average Age

Experienced Board: BLTE's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/26 19:08
End of Day Share Price	2025/12/26 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Belite Bio, Inc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bruce Jackson	Benchmark Company
Jennifer Kim	Cantor Fitzgerald & Co.
Steven Seedhouse	Cantor Fitzgerald & Co.

Belite Bio Management

Management criteria checks 2/4

Key information

Recent management updates

Belite Bio, Inc, Annual General Meeting, Apr 15, 2025

Key Executive notifies of intention to sell stock

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Recent updates

New minor risk - Shareholder dilution

Belite Bio, Inc. Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Forecast to breakeven in 2027

Belite Bio, Inc has completed a Follow-on Equity Offering in the amount of $15.00005 million.

Price target increased by 13% to US$106

Belite Bio Inc. Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for Treatment of Stargardt Disease with Tinlarebant

Belite Bio, Inc. Announces China NMPA Agrees to New Drug Application with Priority Review Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Inc. Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Belite Bio, Inc announced that it expects to receive $124.999936 million in funding from RA Capital Management, L.P., Eventide Asset Management, LLC, Marshall Wace LLP, RTW Investments, LP, Soleus Capital LLC, Vestal Point Capital, LP

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $15.00005 million.

Now 20% overvalued after recent price rise

Price target increased by 10% to US$93.75

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio, Inc. Announces Completion of Enrollment in the Pivotal Global Phase 3 Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio, Inc. Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Price target increased by 7.3% to US$85.00

No longer forecast to breakeven

Belite Bio, Inc, Annual General Meeting, Apr 15, 2025

No longer forecast to breakeven

New minor risk - Shareholder dilution

Belite Bio, Inc. Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON Trial of Tinlarebant in Adolescent Stargardt Disease Subjects

New minor risk - Profitability

Belite Bio, Inc has filed a Follow-on Equity Offering.

Forecast to breakeven in 2027

New minor risk - Share price stability

Price target increased by 18% to US$66.75

Key Executive notifies of intention to sell stock

Director notifies of intention to sell stock

Belite Bio Announces Appointment of Hendrik P. N. Scholl as Chief Medical Officer

Key Executive notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Belite Bio, Inc. Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio, Inc has filed a Follow-on Equity Offering in the amount of $24.999964 million.

Director notifies of intention to sell stock

Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Chief Scientific Officer notifies of intention to sell stock

CFO & Director notifies of intention to sell stock

Director notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 21% to US$45.67

Belite Bio, Inc. Doses First Subject in Pivotal Phase 3 Phoenix Trial Evaluating Oral Tinlarebant for Ga

Belite Bio, Inc. Completes Enrollment in Pivotal Global Phase 3 Dragon Trial Evaluating Oral Tinlarebant for Stargardt Disease

Belite Bio, Inc to Report Q1, 2023 Results on May 10, 2023

Belite Bio, Inc Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)

Less than half of directors are independent

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Belite Bio, Inc Presents 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease At AAO Annual Meeting 2022

Belite Bio Receives Approval of Lbs-008 Phase 3 Clinical Trial in China

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of Lbs-008 in Stargardt Disease in the U.S

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Belite Bio, Inc to Report Q2, 2022 Results on Aug 10, 2022

Belite Bio, Inc Submits Investigational New Drug Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Belite Bio, Inc Presents Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Belite Bio Receives FDA Fast Track Designation For LBS-008

No independent directors

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources